A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

October 22, 2019

Study Completion Date

October 22, 2019

Conditions

PNH

Interventions

DRUG

Pegcetacoplan

Complement (C3) Inhibitor

Trial Locations (3)

Acibadem City Clinic MHAT Tokuda EAD Sofia, Sofia

Specialized Hospital for Active Treatment of Hematologic Diseases EAD, Sofia, Sofia

Klinički centar Srbije, Belgrade